C-Met/HDAC-IN-2

C-Met/HDAC-IN-2 is a highly potent c-Met and HDAC dual inhibitor with IC50s of 18.49 nM and 5.40 nM for HDAC1 and c-Met, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines. c-Met/HDAC-IN-2 can cause G2/M-phase arrest and induce apoptosis in HCT-116. c-Met/HDAC-IN-2 can be used for researching anti-cancer resistance[1].

Product Specifications

CAS Number

[2740495-53-6]

UNSPSC

12352005

Target

Apoptosis; c-Met/HGFR; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/c-met-hdac-in-2.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=NN(C2=CC=CC=C2)C=CC1=O)NC3=CC=C(OC4=CC=NC5=CC(OCCCCCCC(NO)=O)=C(OC)C=C45)C=C3

Molecular Formula

C34H33N5O7

Molecular Weight

623.66

References & Citations

[1]Hu H, Chen F, Dong Y, et al. Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors. Eur J Med Chem. 2020;204:112651.